 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12345678910111213...208209» |
- Sulanda (surufatinib) / Hutchmed, AiRuiKa (camrelizumab) / Elevar Therapeutics
Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3096;
- TheraCIM (nimotuzumab) / Daiichi Sankyo, Biocon, Biotech Pharma, HRS-4642 / Jiangsu Hengrui Pharma
A Phase Ib/II Study of HRS-4642 plus Nimotuzumab in Patients with KRAS G12D-Mutant Advanced Pancreatic Ductal Adenocarcinoma (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3090;
- zeprumetostat (SHR-2554) / Treeline Biosci, AiTan (rivoceranib) / Elevar Therapeutics, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Retlirafusp alfa Combined with Rivoceranib, With or Without Zeprumetostat, in Patients with Advanced Gastric Cancer Who Have Failed First-Line Immunotherapy (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3049;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Two versus Four Cycles of Neoadjuvant Adebrelimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Prospective, Multicenter, Randomized Phase II Trial (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3010;
- garetatug rezetecan (SHR-A1904) / EMD Serono, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
SHR-A1904 plus adebrelimab with/without 5-FU as 1L therapy for CLDN18.2+ advanced GC/GEJC: data from a phase Ib/III study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_3006;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab combined with albumin-bound paclitaxel and cisplatin neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a multi-center, single-arm clinical trial (AURORA-NEO) (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2993;
- ruzaltatug rezetecan (SHR-A2009) / Jiangsu Hengrui Pharma, Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
SHR-A2009 plus adebrelimab (Adebre) with or without bevacizumab (Bev) for pretreated NSCLC: a phase 1b/2 study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2910;
- Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
SHR-A1811 (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2909;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, HRS-4642 / Jiangsu Hengrui Pharma
HRS-4642 Combined with Adebrelimab and Chemotherapy as Firstline Treatment for KRAS G12D Mutant Advanced Non-small Cell Lung Cancer: A Phase 1b/2 Study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2900;
- Avastin (bevacizumab) / Roche, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab plus Bevacizumab and Nab-paclitaxel in Non-squamous NSCLC after Progression on First-line ICI-based therapy: A Phase II Rechallenge Study with Biomarker Analysis (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2895;
- SHR-A2102 / Jiangsu Hengrui Pharma
SHR-A2102, a Nectin-4 ADC, Combined with EGFR-TKI in EGFR-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) After EGFR-TKI Failure: A Multicenter, Open-Label, Phase II Trial (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2881;
- Focus V (anlotinib) / Advenchen, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab combined with Anlotinib and Chemotherapy Neoadjuvant Therapy Resectable Stage II-III Non-Small Cell Lung Cancer (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2816;
- AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma, AiRuiKa (camrelizumab) / Elevar Therapeutics
Bipolar androgen therapy sequential rezvilutamide combined with camrelizumab for patients with mCRPC: A single-arm prospective clinical study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2653;
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Camrelizumab Plus Apatinib for Locally Advanced or Metastatic Malignant Ocular Adnexal Tumors: A Multicenter, Multi-cohort, Single-arm Phase II Trial (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2525;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, JS105 / Shanghai Junshi Bioscience, Risen (Suzhou) Biosci
A Phase 1b/2 Study of JS105 in Combination with Dalpiciclib and Fulvestrant in Patients with Advanced Breast Cancer (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2474;
- SHR-A2102 / Jiangsu Hengrui Pharma
SHR-A2102, a Nectin-4 (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2472;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
Real-World Comparative Study of Pertuzumab- vs Pyrotinib-Based First-Line Regimens in HER2-Positive Advanced Breast Cancer: A Xinjiang Multicenter Study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2452;
- Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, Perjeta (pertuzumab) / Roche
Updated results of SHR-A1811 plus pertuzumab in human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic breast cancer: a phase 1b/2 study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2449;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Dalpiciclib plus Pyrotinib-Based Chemotherapy-Free Regimens as first line treatment in Trastuzumab-Sensitive, HER2-Positive Metastatic Breast Cancer (DAP-HER-02): A Dual-Cohort, Phase II Study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2446;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma
A Study Evaluating the Safety and Efficacy of Pyrotinib Dose Escalation Plus Loperamide Prophylaxis in First-Line Treatment of Advanced HER2-Positive Breast Cancer (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2443;
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Impact of early antibiotic exposure on efficacy of camrelizumab plus rivoceranib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC): a sub-analysis of CARES-310. (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2440;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_1983;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
A randomized, open-label, multicenter phase II study of SHR-8068 plus adebrelimab and gemcitabine/cisplatin (GC) as first-line treatment for advanced biliary tract cancer (BTC) (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_1945;
- AiTan (rivoceranib) / Elevar Therapeutics
Rivoceranib in patients with pretreated metastatic thymic epithelial tumors: phase II multi-center KCSG LU23-09 (THRIVE) trial (Burgos Auditorium - Hall 3) - Jul 17, 2026 - Abstract #ESMO2026ESMO_1537;
- SHR-A2102 / Jiangsu Hengrui Pharma
SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study (Murcia Auditorium - Hall 3) - Jul 17, 2026 - Abstract #ESMO2026ESMO_1000;
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (LARC): The phase 3 UNION trial (Alicante Auditorium - Hall 6) - Jul 17, 2026 - Abstract #ESMO2026ESMO_897;
- | AiTan (rivoceranib) / Elevar Therapeutics, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Enrollment open: SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer (clinicaltrials.gov) - Jul 16, 2026
P2, N=80, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
Not yet recruiting --> Recruiting
- | retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
Biomarker, New P2 trial, Head-to-Head, IO biomarker: An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jul 16, 2026
P2, N=347, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Olinvyk (oliceridine) / Trevena, Sufenta (sufentanil) / Akorn
New trial: RMZ-OLI-ENDO: Remimazolam Combined With Oliceridine for Sedation in Elderly Patients Undergoing Gastrointestinal Endoscopy (clinicaltrials.gov) - Jul 16, 2026
P=N/A, N=240, Not yet recruiting, Sponsor: Baoshan Branch, Renji Hospital, Shanghai Jiao Tong University School of Medicine
- |||||||||| HRS-1780 / Jiangsu Hengrui Pharma
New P2/3 trial: A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension. (clinicaltrials.gov) - Jul 16, 2026
P2/3, N=914, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- | ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment closed: Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes (clinicaltrials.gov) - Jul 15, 2026
P2, N=264, Active, not recruiting, Sponsor: Kailera
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial: Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer (clinicaltrials.gov) - Jul 15, 2026
P2, N=70, Recruiting, Sponsor: Peking Union Medical College Hospital
- | garetatug rezetecan (SHR-A1904) / EMD Serono
New P2 trial: SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study (clinicaltrials.gov) - Jul 14, 2026
P2, N=17, Not yet recruiting, Sponsor: Peking University Cancer Hospital & Institute
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Enrollment open, Trial primary completion date: BJGBYY-IIT-LCYJ-2024-008: Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jul 14, 2026
P2, N=113, Recruiting, Sponsor: Beijing GoBroad Hospital
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2027 --> Mar 2027
- ||||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion, Trial primary completion date: HRS9531-302: the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes? Inadequately Controlled With Diet and Exercise Alone (clinicaltrials.gov) - Jul 14, 2026
P3, N=218, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2027 --> Mar 2027 Active, not recruiting --> Completed | Trial primary completion date: May 2025 --> Jan 2026
- ||| SHR-1703 / Jiangsu Hengrui Pharma
New P1 trial: A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants (clinicaltrials.gov) - Jul 14, 2026
P1, N=84, Not yet recruiting, Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
- |||| Xiidra (lifitegrast) / Bausch Health, NovaTears (perfluorohexyloctane) / Novaliq, Bausch Health, AFT Pharma
Trial completion, Trial completion date, Trial primary completion date: A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease (clinicaltrials.gov) - Jul 14, 2026
P2, N=443, Completed, Sponsor: Bausch & Lomb Incorporated
Active, not recruiting --> Completed | Trial primary completion date: May 2025 --> Jan 2026 Recruiting --> Completed | Trial completion date: Nov 2026 --> May 2026 | Trial primary completion date: Nov 2026 --> May 2026
- | Avida (trastuzumab rezetecan) / Jiangsu Hengrui Pharma
New P2 trial: First-line Therapy With EGFR-TKI Combined With Trastuzumab Rezetecan for Advanced NSCLC Harboring EGFR Mutations Concomitant With HER2 Alterations (clinicaltrials.gov) - Jul 14, 2026
P2, N=35, Not yet recruiting, Sponsor: Yongsheng Wang
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Enrollment open, Real-world evidence: Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer (clinicaltrials.gov) - Jul 13, 2026
P4, N=500, Recruiting, Sponsor: Peking University People's Hospital
Recruiting --> Completed | Trial completion date: Nov 2026 --> May 2026 | Trial primary completion date: Nov 2026 --> May 2026 Not yet recruiting --> Recruiting
- | Enrollment change, Trial completion date, Trial primary completion date: An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (clinicaltrials.gov) - Jul 13, 2026
P2, N=60, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting N=40 --> 60 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Aug 2026 --> Jun 2027
- ||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment closed: HRS9531-302: the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes? Inadequately Controlled With Diet and Exercise Alone (clinicaltrials.gov) - Jul 12, 2026
P3, N=218, Active, not recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
N=40 --> 60 | Trial completion date: Aug 2027 --> Dec 2027 | Trial primary completion date: Aug 2026 --> Jun 2027 Recruiting --> Active, not recruiting
- |||||||||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
New P3 trial: A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 9, 2026
P3, N=690, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Trial completion, Trial completion date, Trial primary completion date: Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer (clinicaltrials.gov) - Jul 8, 2026
P=N/A, N=14, Completed, Sponsor: Fudan University
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2025 --> Jan 2026 | Recruiting --> Completed | Trial completion date: Oct 2026 --> Jun 2026
- rivocibart (SHR-1918) / Jiangsu Hengrui Pharma
Angiopoietin-like 3 antibody rivocibart for homozygous familial hypercholesterolemia (Achgabat (Hall A3)) - Jul 4, 2026 - Abstract #ESC2026ESC_9342;
- AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
Tegileridine for Pain Management Following Total Laparoscopic Hysterectomy: A Randomized Controlled Pilot Trial (Exhibit Hall) - Jul 2, 2026 - Abstract #ASA2026ASA_2680;
Trial primary completion date: Feb 2025 --> Jan 2026 | Recruiting --> Completed | Trial completion date: Oct 2026 --> Jun 2026 Abstract is embargoed at this time.
- || ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Trial completion: HRS9531-105: A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects (clinicaltrials.gov) - Jul 2, 2026
P1, N=32, Completed, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Abstract is embargoed at this time. Recruiting --> Completed
- ||||||| HR17031 / Jiangsu Hengrui Pharma
Trial completion: A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes (clinicaltrials.gov) - Jul 2, 2026
P3, N=393, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed Recruiting --> Completed
- ||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Enrollment change: Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia (clinicaltrials.gov) - Jul 2, 2026
P2, N=108, , Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Completed N=78 --> 108
- |||| AiTan (rivoceranib) / Elevar Therapeutics, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
New P2 trial: A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 2, 2026
P2, N=120, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- |||| HR19042 / Jiangsu Hengrui Pharma
Trial completion: A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. (clinicaltrials.gov) - Jul 2, 2026
P2, N=316, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=78 --> 108 Active, not recruiting --> Completed